

# ANNUAL REPORT

2024/25

# VISION

Better oral health for all Australians

# MISSION

Translating oral health research into  
better health for all Australians

The Australian Taxation Office has endorsed the eviDent Foundation (ABN 81 152 078 487) (ACN 152 078 487) as a Deductible Gift Recipient (DGR) and for charity tax concessions. The eviDent Foundation is registered as a fundraiser in the following states:

Victoria - FR0011984  
Tasmania - C/10516  
New South Wales - CFN/24729  
Queensland - CH3292  
South Australia - CCP3512  
Western Australia - CC23022

Its registered office is located at Level 3, 10 Yarra Street, South Yarra, Victoria, 3141.

eviDent Foundation  
PO Box 9015  
South Yarra VIC 3141

03 8825 4600  
[ask@evident.net.au](mailto:ask@evident.net.au)  
[evident.org.au](http://evident.org.au)

# Chair's Report

---



eviDent is fast approaching the second year of our two-year partnership with ADAVB. Through this partnership agreement we have been able to employ a new Executive Officer Dr Tejashree Kangutkar who brings to the team expertise in the area of dental research and a great deal of enthusiasm. Tee has already proven her worth in opening dialogue with Sydney University in regard to research collaborations and is expanding our collaborations with La Trobe University and University of Adelaide.

The DPBRN is reinvigorated and looking to onboard new research projects. This year the annual eviDent Booster Grant was awarded to:  
*Dr Hasitha Pelenda: Understanding the oral health priorities of older Australians entering aged care.*

The annual eviDent charity walk did not happen this year, however The Heyson Trail walk is planned for June 2026 in conjunction with HUMA Charity.

eviDent has been involved with four national grant applications. Unfortunately, three of these were unsuccessful and the fourth is pending. Despite the strength of the applications this result highlights the difficulty we have as a profession in obtaining funding for research in oral health.

I would like to thank the eviDent Board, DPBRN Committee, other Committee members, our EO and ADAVB support staff for all their help and positivity over the year.

A handwritten signature in black ink that reads "Stephen Cottrell".

**Dr Stephen Cottrell**  
Chair

# Board And Committee Membership

---

Board	Dental Practice-Based Network Committee	Finance and Audit Committee	Development Committee
Dr Stephen Cottrell, Chair	Dr Tony Robertson, Co-Chair <i>retired December 2024</i>	Dr Jeremy Sternson, Chair	Mr Kenneth Harrison AM, Chair
Dr Jan Tennent OAM, Vice Chair	Dr Rita Hardiman, Co-Chair	Dr Felicity Wardlaw, Vice Chair	Dr Parul Marwaha, Vice Chair
Dr Jeremy Sternson, Treasurer	Dr Jeremy Sternson	Mr Tan Nguyen	Ms Karen Escobar
Dr Denise Addison (aka Bailey) <i>retired November 2024</i>	Dr Jaafar Abduo		Dr Rachelle Welti
Prof Stuart Dashper	Dr Antonio Celentano		Dr Gavin Quek
Mr Kenneth Harrison AM	A/Prof Nicola Cirillo		
	Dr Jodie Heap		
	Dr Tracey Huntley		
	Clinical A/Prof Mark Evans		
	A/Prof Santosh Tadakamadla		
	Dr Sabine Selbach		

# Objectives

---

**The object for which the company is established is to promote the prevention and control of dental and oral diseases in human beings by:**

- Supporting dental practice-based research into dental and oral disease
- Dissemination of information about dental and oral disease, their prevention, and control to health professionals and the public
- Supporting development of relevant aids and equipment and/or its provision for sufferers of dental and oral disease
- Facilitating development and implementation of cooperative, cross-disciplinary approaches to the treatment and prevention of dental and oral disease
- Supporting and promoting the outcomes of scientific research about how to detect, prevent, and treat dental and oral disease
- Supporting the training of health professionals to conduct scientific research about dental and oral disease
- Informing health professionals and carers about methods of controlling dental and oral disease
- Evaluation of health programs and processes to prevent or control dental and oral disease
- Seeking funding from grant-giving bodies, trusts, foundations, corporate sponsors, members of the dental community and public
- Doing all other lawful things that are incidental or conducive to achieving its object.

# Treasurer's Report

---



Once again it has been a pleasure to be the treasurer of the eviDent Foundation for the 2024/25 financial year. The Foundation had minimal activity in the previous financial year after the loss of our CEO, but this has now started to change.

This year saw an evolution of eviDent's partnership with ADAVB to advance practice-based research into dental and oral disease to include financial support for the Foundation to appoint its first employee.

Following the appointment of its Executive Officer in December 2024, eviDent was able to recommence normal day-to-day operations, and in particular its fundraising activities and university collaborations to assist the Foundation achieve its goals.

In the 2024/25 Financial Statements you will see:

- a revenue increase compared with the prior year, due mainly to the contribution from ADAVB under the new Partnership Agreement; and
- that despite the global downward trend of markets, eviDent's investment portfolio did surprisingly well, although total dividends were down on the prior year.

Our new Executive Officer worked diligently to manage the Foundation's expenses, which were kept low across the year.

eviDent's surplus at the end of 2024/25 was approximately 15K up on the previous year.

Overall, performance this year has laid the groundwork for future years to allow eviDent to continue to grow financially and maintain a focus on sustainability.

**Dr Jeremy Sternson**  
**Treasurer**

# Executive Officer's Report

---



I commenced as the Executive Officer of the eviDent Foundation in December 2024. With a background in clinical dentistry and a PhD in dental public health, I have long been committed to strengthening the link between research and day-to-day dental practice. This personal alignment with eviDent's purpose has made it a privilege to contribute to the organisation's work.

Since stepping into the role, I have focused on strengthening eviDent's relationships with universities in Victoria and interstate. During the year I had the opportunity to meet with final year dental students and early-career dentists, to inform them about eviDent. Introducing eviDent to students and clinicians in the early stages of their careers is an important opportunity to encourage their future engagement with research and commitment to practicing evidence-based care.

Working directly with experienced clinicians has been a highlight of my time at eviDent. Many reached out to me with observations or ideas stemming from their daily practice, and I was able to guide them through the process of shaping their thoughts into research concepts. Describing eviDent's processes, helping clinicians understand how their ideas can be developed further, and showing them the support they can expect through eviDent has been particularly meaningful.

I have also been actively involved in eviDent's strategic planning work. Contributing to discussions about the organisation's direction and future priorities has reinforced the importance of strong partnerships with clinicians, researchers and like-minded professional organisations. It's essential to ensure that eviDent remains responsive to the needs of the profession while promoting high standards for practice-based research.

Overall, the past year has been a significant period of growth and engagement, for myself and the organisation. I relish the opportunity to represent eviDent and to contribute to its mission and I look forward to continuing to advance high-quality oral health research that benefits the dental community and the wider public.

**Dr Tejashree Kangutkar**  
**Executive Officer**

# How eviDent supports clinicians and organisations

---

The strength of eviDent's work lies in the way we bring clinical insight and academic leadership together. Throughout 2024/25, eviDent has continued to support clinicians and organisations seeking a clear, ethical, and academically grounded pathway for research. By offering pathways, expert review, and collaborative guidance, eviDent helps ensure that new ideas can evolve into research studies with the potential to be of lasting value to the profession.

New ideas often arise out of curiosity that is sparked in clinical settings. Clinicians regularly notice patterns, challenges or unexpected treatment responses that prompt important questions about patient care. Turning these real-world observations into meaningful research, however, can be difficult without access to academic expertise or the time needed to navigate research requirements. eviDent helps bridge this gap by providing a supported and coordinated pathway for clinicians who wish to pursue research alongside their ongoing clinical responsibilities.

When a clinician approaches eviDent with an idea or research concept, we connect them with a suitable Chief Investigator, who is frequently an academic with specialised knowledge in the relevant field. This collaboration brings together clinical experience and academic rigour, enabling the development of clear research questions, robust study designs and well-prepared ethics submissions. Through this pathway, clinicians receive the research guidance they need while remaining firmly rooted in practice-based realities.

Central to the success of eviDent's pathway is the oversight provided by the Dental Practice-Based Research Network (DPBRN) committee. Made up of senior academics and experienced clinicians, the DPBRN committee reviews every proposal that seeks eviDent endorsement and support. Their assessment ensures that only those proposals that align with eviDent's mission, meet NHMRC ethical standards, and have the potential to generate research outcomes that are feasible to translate to clinical practice, progress to become eviDent projects. Thereby clinicians can be confident that their involvement in a research project will contribute safe, reliable and translatable insights to the profession.

eviDent's independent review process also offers significant assurance to partner organisations. Professional associations, clinics and networks rely on eviDent to triage research requests involving their members with consistency, transparency and academic integrity. Knowing that every study has undergone rigorous scrutiny strengthens a partner organisation's credibility, protects the welfare of its' members and staff, and ensures that research findings shared with clinicians are grounded in scientific merit.

eviDent projects receive ongoing support throughout their lifecycle. We assist with onboarding, co-branding, recruitment planning for study participants and the review of study materials to ensure they are ethical, clear and compliant with privacy and advertising standards. As projects progress, we remain available to research teams for continued guidance and help to maintain momentum and address challenges as they arise.

The impact of eviDent's support is especially visible when project findings are ready to be shared. eviDent facilitates dissemination through multiple professional channels, including scientific journals, the eviDent Research Showcase, newsletters, websites and conferences. Thus eviDent ensures that new knowledge reaches the broader dental community and ultimately contributes to improved clinical practice. For clinicians, taking part in eviDent studies provides recognition, skill development and the opportunity to contribute meaningfully to the evidence base. For organisations, it reinforces their commitment to supporting high-quality, practice-based research.

At its core, eviDent is grounded in partnership and shared purpose. By supporting clinicians to explore the questions that arise in real-world practice, and by offering organisations a trusted pathway for managing research activity, eviDent creates an environment where high-quality research can thrive. Our role is to connect the right people, promote strong ethical and scientific standards, and guide every project with care and clarity.

As eviDent looks to the future, our focus remains steadfast on making research accessible, strengthening relationships across the profession, and ensuring that clinicians and organisations feel supported at every stage of the research journey. Through this thoughtful and collaborative work, eviDent will continue to contribute to a stronger evidence base and better oral health outcomes for all Australians.

**Dr Tejashree Kangutkar**  
**Executive Officer**

# Directors' Report

Your Directors present this report on the company for the financial year ended 30 June 2025.

## Directors

The names of each person who has been a director during the year and to the date of this report are:

- Dr Denise Addison (aka Bailey) *to November 2024*
- Dr Stephen Cottrell
- Prof Stuart Dashper
- Mr Kenneth Harrison AM
- Dr Jeremy Sternson
- Dr Jan Tennent OAM

Directors have been in office since the start of the financial year to the date of this report unless otherwise stated.

## Principal activities

The principal activity of the company during the financial year was facilitating dental practice-based research into dental and oral disease.

The company's short-term objectives are to:

- Grow the research network in a sustainable manner
- Facilitate and support practice-based research
- Disseminate research findings
- Ensure resources enable achievement of goals
- Strengthen stakeholder relations
- Raise the profile of the Foundation
- Promote strong ethical and scientific standards.

The company's long-term objectives are to:

- Facilitate the rapid translation of research findings into clinical practice
- Drive improvements in care coordination
- Stimulate oral healthcare innovation
- Enable improved health outcomes for the community.

## Strategies

To achieve its stated objectives, the company has adopted the following strategies:

- Support collaborative research
- Identify interdisciplinary projects with potential to maximise innovative practice and improve referral pathways
- Facilitate research that creates the evidence base for clinical decision making
- Support the development of evidence-based guidelines and resources for use by practitioners, funding agencies, patients and others
- Collaborate with key partners to influence health policy

As the company has only been operational since July 2011, the Directors consider it would be premature to apply industry benchmarks to assessment of performance other than to assure themselves that the company has the funding to pay expenses as and when they fall due.

The Partnership Agreement with the ADAVB details the administrative and financial support the ADAVB will provide to eviDent between 2024 and 2026, which collectively will contribute positively towards the operations of eviDent. As the eviDent Foundation's investment fund grows, the Directors expect that it will move to cover its own administrative costs.

## Meetings of Directors

Director	Number eligible to attend	Number attended
Denise Addison (aka Bailey)	1	1
Stephen Cottrell	3	3
Stuart Dashper	3	2
Ken Harrison	3	0
Jeremy Sternson	3	2
Jan Tennent	3	3

---

## Contributions on Winding Up

The company is incorporated under the Corporations Act 2001 and is a company limited by guarantee. If the company is wound up, the Constitution states that each member is required to contribute a maximum of \$5 each towards meeting any outstanding obligations of the company.

At 30 June 2025, the total amount that members of the company are liable to contribute if the company is wound up is \$5.

## Governance

The eviDent Foundation is managed by its directors. The company must have at least four directors, or if higher the number specified by the law and shall have no more than nine directors.

In 2024/25, the eviDent Foundation had six directors, made up of the Chair, Vice Chair, Treasurer and three others.

As at 30 June 2025, the Board was supported by the following ADAVB staff:

Ms Emma Hou – honorary finance manager

With an annual revenue under \$500,000, the eviDent Foundation is recognised by the Australian Charities and Not-for-profit Commission (ACNC) as a 'Small charity' and as such is not required to have its financial reports audited or reviewed.

The financial statements and notes, as set out on pages 11 to 22, are unaudited.

Signed in accordance with a resolution of the Board of Directors.



Dr Stephen Cottrell  
Chair

Dated 1 December 2025

---

# Financial Statements For The Year Ended 30 June 2025

**STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 30 JUNE 2025  
UNAUDITED**

	Note	2025	2024
		\$	\$
<b>Revenue from continuing operations</b>	3	8,790	32,346
Other revenue	3	92,740	22,204
Booster Grant expenses		-	(18,090)
Administration expenses		(5,078)	(4,115)
Other expenses		(61,264)	(9,175)
<b>Surplus before income tax</b>		<b>35,187</b>	<b>23,170</b>
Income tax expense	1(a)	-	-
<b>Surplus for the year</b>		<b>35,187</b>	<b>23,170</b>
<b>Other comprehensive income</b>			
Equity instruments at fair value through other comprehensive income - fair value changes		10,407	7,175
<b>Total comprehensive income for the year</b>		<b>45,595</b>	<b>30,345</b>
<b>Surplus attributable to:</b>			
Members of the entity		45,595	30,345
<b>Surplus for the year</b>		<b>45,595</b>	<b>30,345</b>
<b>Total comprehensive income attributable to:</b>			
Members of the entity		45,595	30,345
<b>Total comprehensive income for the year</b>		<b>45,595</b>	<b>30,345</b>

The accompanying notes form part of these financial statements.

**STATEMENT OF FINANCIAL POSITION**  
**AS AT 30 JUNE 2025**  
**UNAUDITED**

	Note	2025	2024
		\$	\$
<b>Assets</b>			
<b>Current Assets</b>			
Cash and cash equivalents	5	212,952	179,226
Trade and other receivables	7	1,444	2,945
<b>Total current assets</b>		<b>214,396</b>	<b>182,171</b>
 <b>Non-current assets</b>			
Financial assets	6	337,576	317,669
Office equipment		1,168	-
<b>Total non-current assets</b>		<b>338,744</b>	<b>317,669</b>
<b>Total assets</b>		<b>553,140</b>	<b>499,840</b>
 <b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	8	11,739	4,034
<b>Total current liabilities</b>		<b>11,739</b>	<b>4,034</b>
<b>Total liabilities</b>		<b>11,739</b>	<b>4,034</b>
<b>Net assets</b>		<b>541,400</b>	<b>495,806</b>
 <b>Equity</b>			
Reserves		(999)	(11,406)
Accumulated surplus		542,399	507,212
<b>Total equity</b>		<b>541,400</b>	<b>495,806</b>

The accompanying notes form part of these financial statements.

STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 30 JUNE 2025  
UNAUDITED

	Accumulated surplus	Reserves	Total
	\$	\$	\$
<b>Balance at 1 July 2023</b>	484,042	(18,581)	465,461
Surplus for the year	23,170	-	23,170
Other comprehensive income	-	7,175	7,175
<b>Total comprehensive income for the year</b>	<b>23,170</b>	<b>7,175</b>	<b>30,345</b>
<b>Balance at 30 June 2024</b>	<b>507,212</b>	<b>(11,406)</b>	<b>495,806</b>
<b>Balance at 1 July 2024</b>	<b>507,212</b>	<b>(11,406)</b>	<b>495,806</b>
Surplus for the year	35,187	-	35,187
Other comprehensive income	-	10,407	10,407
<b>Total comprehensive income for the year</b>	<b>35,187</b>	<b>10,407</b>	<b>45,594</b>
<b>Balance at 30 June 2025</b>	<b>542,399</b>	<b>(999)</b>	<b>541,400</b>

The accompanying notes form part of these financial statements.

**STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 30 JUNE 2025**  
**UNAUDITED**

	Note	2025	2024
		\$	\$
<b>Cash flow from operating activities</b>			
Receipts from related parties		-	-
Donations and Other Income received		90,654	46,014
Payments to suppliers, employees and others		(58,999)	(30,223)
Finance income		23,147	29,379
<b>Net cash provided by operating activities</b>	10(b)	<b>54,802</b>	<b>45,170</b>
<b>Cash flow from investing activities</b>			
Proceeds from sale of investments		-	-
Purchase of investments		(21,076)	(26,251)
<b>Net cash used in investing activities</b>		<b>(21,076)</b>	<b>(26,251)</b>
Net increase in cash and cash equivalents		33,726	18,919
Cash and cash equivalents at beginning of financial year		179,226	160,307
<b>Net cash and cash equivalents</b>	10(a)	<b>212,952</b>	<b>179,226</b>

The accompanying notes form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025  
UNAUDITED

**NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

The financial statements cover eviDent Foundation Limited as a single entity. eviDent Foundation Limited is a company limited by guarantee, incorporated under the *Corporations Act 2001*.

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

**New or amended Accounting Standards and Interpretations adopted**

The company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

**Basis of preparation**

In the directors' opinion, the company is not a reporting entity because there are no users dependent on general purpose financial statements.

These are special purpose financial statements that have been prepared for the purposes of complying with the Australian Charities and Not-for-profits Commission Act 2012 and requirements to prepare and distribute financial statements to the members of eviDent Foundation Limited. The directors have determined that the accounting policies adopted are appropriate to meet the needs of the members of eviDent Foundation Limited.

These financial statements have been prepared in accordance with the recognition and measurement requirements specified by the Australian Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') and the disclosure requirements of AASB 101 'Presentation of Financial Statements', AASB 107 'Statement of Cash Flows', AASB 108 'Accounting Policies, Changes in Accounting Estimates and Errors', AASB 1048 'Interpretation of Standards' and AASB 1054 'Australian Additional Disclosures', as appropriate for not-for-profit oriented entities.

*Historical cost convention*

The financial statements have been prepared under the historical cost convention.

**(a) Income Tax**

The company has been granted exemption from income tax under Subdivision 50-B of the Income Tax Assessment Act 1997; accordingly, no provision for income tax has been made.

**(b) Revenue**

The company has determined that all income that it receives is recognised as income of not-for-profit entities in accordance with AASB 1058.

*Interest revenue*

Interest revenue is recognised using the effective interest rate method, which, for floating rate financial assets is the rate inherent in the instrument.

*Fundraising and donations*

Fundraising and donations collected are recognised as revenue when the company gains control of the funds. All revenue is stated net of the amount of goods and services tax (GST).

**(c) Cash and Cash Equivalents**

Cash and short-term deposits in the statement of financial position comprise cash at bank and in hand and short-term deposits with an original maturity of three months or less. For the purposes of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of outstanding bank overdrafts.

The accompanying notes form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025  
UNAUDITED

**NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**(d) Financial Instruments**

*Fair Value:*

The fair values of assets and liabilities, the fair value approximates their carrying value. No financial assets and financial liabilities are readily traded on organised markets in standardised form.

The aggregate fair values and carrying amounts of the Company's financial assets and financial liabilities are disclosed in the Statement of Financial Position and in the notes to the financial statements.

After initial recognition these are measured at amortised cost using the effective interest method.

*Impairment of financial assets*

AASB 9 Financial Instruments' impairment requirements use more forward-looking information to recognise expected credit losses, other than for trade and other receivables, where the loss allowance is the expected lifetime credit losses. The Company has assessed the impairment on its receivables and has concluded that no allowance is necessary.

*Classification of financial liabilities*

The Company's financial liabilities include trade and other payables. Such financial liabilities are initially measured at fair value and are subsequently measured at amortised cost using the effective interest method.

*Derecognition*

Financial assets are derecognised where the contractual rights to receipt of cash flows expire, or the asset is transferred to another party whereby the entity no longer has any significant continuing involvement in the risks and benefits associated with the asset. Financial liabilities are derecognised where the related obligations are either discharged, cancelled or expire. The difference between the carrying value of the financial liability extinguished or transferred to another party and the fair value of consideration paid, including the transfer of non-cash assets or liabilities assumed, is recognised in profit or loss.

**(e) Goods and Services Tax (GST)**

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. In these circumstances, the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST.

Cash flows are presented in the cash flow statement on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

**(f) Comparative Figures**

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

The accompanying notes form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025  
UNAUDITED

**NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**(g) Investments and other financial assets**

Investments and other financial assets, other than investments in associates, are initially measured at fair value. Transaction costs are included as part of the initial measurement, except for financial assets at fair value through profit or loss. Such assets are subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined based on both the business model within which such assets are held and the contractual cash flow characteristics of the financial asset unless an accounting mismatch is being avoided.

Financial assets are derecognised when the rights to receive cash flows have expired or have been transferred and the company has transferred substantially all the risks and rewards of ownership. When there is no reasonable expectation of recovering part or all of a financial asset, its carrying value is written off.

*Financial assets at fair value through profit or loss*

Financial assets not measured at amortised cost or at fair value through other comprehensive income are classified as financial assets at fair value through profit or loss. Typically, such financial assets will be either: (i) held for trading, where they are acquired for the purpose of selling in the short-term with an intention of making a profit, or a derivative; or (ii) designated as such upon initial recognition where permitted. Fair value movements are recognised in profit or loss.

*Financial assets at fair value through other comprehensive income*

Financial assets at fair value through other comprehensive income include equity investments which the company intends to hold for the foreseeable future and has irrevocably elected to classify them as such upon initial recognition.

*Impairment of financial assets*

The company recognises a loss allowance for expected credit losses on financial assets which are either measured at amortised cost or fair value through other comprehensive income. The measurement of the loss allowance depends upon the company's assessment at the end of each reporting period as to whether the financial instrument's credit risk has increased significantly since initial recognition, based on reasonable and supportable information that is available, without undue cost or effort to obtain.

Where there has not been a significant increase in exposure to credit risk since initial recognition, a 12-month expected credit loss allowance is estimated. This represents a portion of the asset's lifetime expected credit losses that is attributable to a default event that is possible within the next 12 months. Where a financial asset has become credit impaired or where it is determined that credit risk has increased significantly, the loss allowance is based on the asset's lifetime expected credit losses. The amount of expected credit loss recognised is measured on the basis of the probability weighted present value of anticipated cash shortfalls over the life of the instrument discounted at the original effective interest rate.

For financial assets mandatorily measured at fair value through other comprehensive income, the loss allowance is recognised in other comprehensive income with a corresponding expense through profit or loss. In all other cases, the loss allowance reduces the asset's carrying value with a corresponding expense through profit or loss.

The accompanying notes form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025  
UNAUDITED

**NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)**

**(h) Current and non-current classification**

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the company's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the company's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

**(i) Accounting Standards issued but not yet effective and not adopted early:**

Certain new and revised accounting standards have been issued but are not effective for the accounting period ended 30 June 2025.

The following accounting standards have not been applied to these financial statements. The Company is reviewing its existing policies and assessing the potential implications of the accounting standard which includes:

AASB 2021-1 Amendments to Australian Accounting Standards – Classification of Liabilities as Current or Non-Current.

AASB 2021-2 Amendments to Australian Accounting Standards – Disclosure of Accounting Policies and Definition of Accounting Estimates.

The accompanying notes form part of these financial statements.

**NOTES TO THE FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 JUNE 2025**  
**UNAUDITED**

**NOTE 2: CRITICAL ACCOUNTING ESTIMATES AND JUDGEMENTS**

The Company evaluates estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the company.

	<b>2025</b>	<b>2024</b>
	\$	\$
<b>NOTE 3: REVENUE FROM CONTINUING OPERATIONS</b>		
<b>Revenue</b>		
Donations received	8,790	-
Donations received and Fundraising events	-	32,346
Partnership Agreement Instalment from ADAVB	80,000	-
	<b>88,790</b>	<b>32,346</b>

**Other revenue**

Dividends received	12,481	21,916
Interest income	258	288
Other income	0	0
	<b>12,739</b>	<b>22,204</b>

**NOTE 4: AUDITOR'S REMUNERATION**

Remuneration for the auditor for:

- auditing or reviewing the financial report	0	0
	<b>0</b>	<b>0</b>

**NOTE 5: CASH AND CASH EQUIVALENTS**

Cash at bank and cash on hand	212,952	179,226
	<b>212,952</b>	<b>179,226</b>

**NOTE 6: FINANCIAL ASSETS**

Financial assets at fair value through other comprehensive income	337,576	317,669
	<b>337,576</b>	<b>317,669</b>

**NOTE 7: TRADE AND OTHER RECEIVABLES****Current**

Amount Receivable from the Parent Entity	0	0
Other receivables	1,444	2945
	<b>1,444</b>	<b>2945</b>

**NOTE 8: TRADE AND OTHER PAYABLES****Current**

Accrued expenses	11,739	4,034
	<b>11,739</b>	<b>4,034</b>

The accompanying notes form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS  
FOR THE YEAR ENDED 30 JUNE 2025  
UNAUDITED

**NOTE 9: CAPITAL MANAGEMENT**

The company is a company limited by guarantee and its sole source of funding is retained profits. The finance and audit committee operates under policies approved by the board of directors. Risk management policies are approved and reviewed by the board on a regular basis. These include credit risk policies and future cash flow requirements. The company's policy is not to have any borrowings and accordingly its liabilities and commitments are solely trade payables. Management effectively manages the entity's capital by assessing the entity's financial risks and responding to the changes in these risks and in the market. The company seeks to make profits each financial year. Profit provides capital and cash flow to enable the company to fund its operation.

**NOTE 10: CASH FLOW INFORMATION**

*(a) Reconciliation of cash*

Cash at the end of the financial year as shown in the statement of cash flows is reconciled to items in the statement of financial position as follows:

	2025	2024
	\$	\$
Cash and cash equivalents	<u>212,952</u>	<u>179,226</u>

*(b) Reconciliation of cash flow from operations with surplus after tax*

	2025	2024
	\$	\$
Surplus after income tax	<u>45,595</u>	<u>30,345</u>

Adjustments for:

Changes in assets and liabilities:

(Increase)/decrease in trade and other receivables	1,864	13,668
(Decrease)/increase in trade payables	7,706	862
(Increase)/decrease in prepayments	(363)	295
Net cash from operating activities	<u>54,802</u>	<u>45,170</u>

The accompanying notes form part of these financial statements.

NOTES TO THE FINANCIAL STATEMENTS FOR  
THE YEAR ENDED 30 JUNE 2025  
UNAUDITED

**NOTE 11: MEMBERS' GUARANTEE**

The company is limited by guarantee. If the company is wound up the Constitution states that each member is required to contribute a maximum of \$5 towards meeting any outstanding obligations of the entity. As at 30 June 2025 there was one member.

**NOTE 12: EVENTS AFTER THE REPORTING DATE**

No matters or circumstances have arisen since the end of the financial period, which significantly affected or may affect the operations of the company.

**NOTE 13: CONTINGENT LIABILITIES**

At reporting date for the period ending 30 June 2025, there are no contingent liabilities.

**NOTE 14: COMPANY'S DETAILS**

The registered office and principal place of business of the company is:

Level 3, 10 Yarra Street  
South Yarra VIC 3141

The accompanying notes form part of these financial statements.

# Directors' Declaration

---

The directors have determined that the company is not a reporting entity and that this special purpose financial report should be prepared in accordance with the accounting policies described in Note 1 to the financial statements.

1. The financial statements and notes, as set out on pages 11 to 22, are in accordance with the Australian Charities and Not-for-Profits Commission Act 2012 and:
  - comply with the Accounting Standards applicable to the company; and
  - give a true and fair view of the financial position as at 30 June 2025 and of the performance of the company for the year ended on that date of the company in accordance with the accounting policies described in NOTE 1 of the financial statements.
2. In the directors' opinion there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors.



Dr Stephen Cottrell  
Chair

Dated 1 December 2025

## Statement by Principal Accounting Officer

---

I, Stephen Cottrell being the person in charge of the preparation of the accompanying accounts of the eviDent Foundation Limited, being the Statement of Profit or Loss and Other Comprehensive Income for the year ended 30 June 2025 and the Statement of Financial Position as at 30 June 2025 of the eviDent Foundation, state that to the best of my knowledge and belief such accounts present fairly the state of affairs of the Company as at 30 June 2025 and of its results for the year then ended.



Dr Stephen Cottrell  
Chair

Dated 1 December 2025



# Thank you to our donors

Every contribution, no matter how large or small, helps strengthen the work of the eviDent Foundation to improve oral health outcomes and advance evidence-based care across the community.

The eviDent Foundation Board and Management extend their sincere appreciation to all donors for their invaluable support throughout the year.